Cargando…
Development and Validation of a Computational Model for Androgen Receptor Activity
[Image: see text] Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2016
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396026/ https://www.ncbi.nlm.nih.gov/pubmed/27933809 http://dx.doi.org/10.1021/acs.chemrestox.6b00347 |
_version_ | 1783229990513410048 |
---|---|
author | Kleinstreuer, Nicole C. Ceger, Patricia Watt, Eric D. Martin, Matthew Houck, Keith Browne, Patience Thomas, Russell S. Casey, Warren M. Dix, David J. Allen, David Sakamuru, Srilatha Xia, Menghang Huang, Ruili Judson, Richard |
author_facet | Kleinstreuer, Nicole C. Ceger, Patricia Watt, Eric D. Martin, Matthew Houck, Keith Browne, Patience Thomas, Russell S. Casey, Warren M. Dix, David J. Allen, David Sakamuru, Srilatha Xia, Menghang Huang, Ruili Judson, Richard |
author_sort | Kleinstreuer, Nicole C. |
collection | PubMed |
description | [Image: see text] Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more rapidly and inexpensively identify potential androgen-active chemicals. We integrated 11 HTS ToxCast/Tox21 in vitro assays into a computational network model to distinguish true AR pathway activity from technology-specific assay interference. The in vitro HTS assays probed perturbations of the AR pathway at multiple points (receptor binding, coregulator recruitment, gene transcription, and protein production) and multiple cell types. Confirmatory in vitro antagonist assay data and cytotoxicity information were used as additional flags for potential nonspecific activity. Validating such alternative testing strategies requires high-quality reference data. We compiled 158 putative androgen-active and -inactive chemicals from a combination of international test method validation efforts and semiautomated systematic literature reviews. Detailed in vitro assay information and results were compiled into a single database using a standardized ontology. Reference chemical concentrations that activated or inhibited AR pathway activity were identified to establish a range of potencies with reproducible reference chemical results. Comparison with existing Tier 1 AR binding data from the U.S. EPA Endocrine Disruptor Screening Program revealed that the model identified binders at relevant test concentrations (<100 μM) and was more sensitive to antagonist activity. The AR pathway model based on the ToxCast/Tox21 assays had balanced accuracies of 95.2% for agonist (n = 29) and 97.5% for antagonist (n = 28) reference chemicals. Out of 1855 chemicals screened in the AR pathway model, 220 chemicals demonstrated AR agonist or antagonist activity and an additional 174 chemicals were predicted to have potential weak AR pathway activity. |
format | Online Article Text |
id | pubmed-5396026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | American Chemical
Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-53960262017-04-20 Development and Validation of a Computational Model for Androgen Receptor Activity Kleinstreuer, Nicole C. Ceger, Patricia Watt, Eric D. Martin, Matthew Houck, Keith Browne, Patience Thomas, Russell S. Casey, Warren M. Dix, David J. Allen, David Sakamuru, Srilatha Xia, Menghang Huang, Ruili Judson, Richard Chem Res Toxicol [Image: see text] Testing thousands of chemicals to identify potential androgen receptor (AR) agonists or antagonists would cost millions of dollars and take decades to complete using current validated methods. High-throughput in vitro screening (HTS) and computational toxicology approaches can more rapidly and inexpensively identify potential androgen-active chemicals. We integrated 11 HTS ToxCast/Tox21 in vitro assays into a computational network model to distinguish true AR pathway activity from technology-specific assay interference. The in vitro HTS assays probed perturbations of the AR pathway at multiple points (receptor binding, coregulator recruitment, gene transcription, and protein production) and multiple cell types. Confirmatory in vitro antagonist assay data and cytotoxicity information were used as additional flags for potential nonspecific activity. Validating such alternative testing strategies requires high-quality reference data. We compiled 158 putative androgen-active and -inactive chemicals from a combination of international test method validation efforts and semiautomated systematic literature reviews. Detailed in vitro assay information and results were compiled into a single database using a standardized ontology. Reference chemical concentrations that activated or inhibited AR pathway activity were identified to establish a range of potencies with reproducible reference chemical results. Comparison with existing Tier 1 AR binding data from the U.S. EPA Endocrine Disruptor Screening Program revealed that the model identified binders at relevant test concentrations (<100 μM) and was more sensitive to antagonist activity. The AR pathway model based on the ToxCast/Tox21 assays had balanced accuracies of 95.2% for agonist (n = 29) and 97.5% for antagonist (n = 28) reference chemicals. Out of 1855 chemicals screened in the AR pathway model, 220 chemicals demonstrated AR agonist or antagonist activity and an additional 174 chemicals were predicted to have potential weak AR pathway activity. American Chemical Society 2016-11-18 2017-04-17 /pmc/articles/PMC5396026/ /pubmed/27933809 http://dx.doi.org/10.1021/acs.chemrestox.6b00347 Text en Copyright © 2016 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Kleinstreuer, Nicole C. Ceger, Patricia Watt, Eric D. Martin, Matthew Houck, Keith Browne, Patience Thomas, Russell S. Casey, Warren M. Dix, David J. Allen, David Sakamuru, Srilatha Xia, Menghang Huang, Ruili Judson, Richard Development and Validation of a Computational Model for Androgen Receptor Activity |
title | Development and
Validation of a Computational Model
for Androgen Receptor Activity |
title_full | Development and
Validation of a Computational Model
for Androgen Receptor Activity |
title_fullStr | Development and
Validation of a Computational Model
for Androgen Receptor Activity |
title_full_unstemmed | Development and
Validation of a Computational Model
for Androgen Receptor Activity |
title_short | Development and
Validation of a Computational Model
for Androgen Receptor Activity |
title_sort | development and
validation of a computational model
for androgen receptor activity |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396026/ https://www.ncbi.nlm.nih.gov/pubmed/27933809 http://dx.doi.org/10.1021/acs.chemrestox.6b00347 |
work_keys_str_mv | AT kleinstreuernicolec developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT cegerpatricia developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT wattericd developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT martinmatthew developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT houckkeith developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT brownepatience developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT thomasrussells developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT caseywarrenm developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT dixdavidj developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT allendavid developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT sakamurusrilatha developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT xiamenghang developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT huangruili developmentandvalidationofacomputationalmodelforandrogenreceptoractivity AT judsonrichard developmentandvalidationofacomputationalmodelforandrogenreceptoractivity |